GBIO Stock Overview
Develops non-viral genetic medicines for the treatment of rare and prevalent diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Generation Bio Co. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.37 |
| 52 Week High | US$4.65 |
| 52 Week Low | US$1.10 |
| Beta | 2.82 |
| 11 Month Change | -38.29% |
| 3 Month Change | -48.30% |
| 1 Year Change | 13.22% |
| 33 Year Change | -92.13% |
| 5 Year Change | n/a |
| Change since IPO | -94.45% |
Recent News & Updates
Recent updates
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
May 01
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Dec 07Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth
Jul 11We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely
Mar 11Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans
Nov 19We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely
Aug 05Generation Bio GAAP EPS of -$0.66 misses by $0.04
Aug 04Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth
Apr 20Generation Bio: High-Risk, Medium-To-Low-Reward
Dec 30We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Nov 11We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Jul 28Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation
Mar 08Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares
Jan 14
Generation Bio's insiders on buying spree, stock +4%
Jan 13Generation Bio prices equity offering at $24.50
Jan 07Generation Bio files to offer 7.5M shares
Jan 04Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?
Dec 27Generation Bio EPS misses by $0.01
Nov 10Shareholder Returns
| GBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.0% | -3.7% | 0.3% |
| 1Y | 13.2% | 15.2% | 31.1% |
Return vs Industry: GBIO underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: GBIO underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| GBIO volatility | |
|---|---|
| GBIO Average Weekly Movement | 11.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GBIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GBIO's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 174 | Geoff McDonough | generationbio.com |
Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system.
Generation Bio Co. Fundamentals Summary
| GBIO fundamental statistics | |
|---|---|
| Market cap | US$88.17m |
| Earnings (TTM) | -US$145.47m |
| Revenue (TTM) | US$18.58m |
4.9x
P/S Ratio-0.6x
P/E RatioIs GBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GBIO income statement (TTM) | |
|---|---|
| Revenue | US$18.58m |
| Cost of Revenue | US$60.02m |
| Gross Profit | -US$41.44m |
| Other Expenses | US$104.04m |
| Earnings | -US$145.47m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.18 |
| Gross Margin | -222.99% |
| Net Profit Margin | -782.87% |
| Debt/Equity Ratio | 0% |
How did GBIO perform over the long term?
See historical performance and comparison